%0 Journal Article
%T Single-cell sequencing analysis characterizes common and cell-lineage-specific mutations in a muscle-invasive bladder cancer
%A Yingrui Li
%A Xun Xu
%A Luting Song
%A Yong Hou
%A Zesong Li
%A Shirley Tsang
%A Fuqiang Li
%A Kate Im
%A Kui Wu
%A Hanjie Wu
%A Xiaofei Ye
%A Guibo Li
%A Linlin Wang
%A Bo Zhang
%A Jie Liang
%A Wei Xie
%A Renhua Wu
%A Hui Jiang
%A Xiao Liu
%A Chang Yu
%A Hancheng Zheng
%A Min Jian
%A Liping Nie
%A Lei Wan
%A Min Shi
%A Xiaojuan Sun
%A Aifa Tang
%A Guangwu Guo
%A Yaoting Gui
%A Zhiming Cai
%A Jingxiang Li
%A Wen Wang
%A Zuhong Lu
%A Xiuqing Zhang
%A Lars Bolund
%A Karsten Kristiansen
%A Jian Wang
%A Huanming Yang
%A Michael Dean
%A Jun Wang
%J GigaScience
%D 2012
%I BioMed Central
%R 10.1186/2047-217x-1-12
%X We carried out single-cell exome sequencing of 66 individual tumor cells from a muscle-invasive bladder transitional cell carcinoma (TCC). Analyses of the somatic mutant allele frequency spectrum and clonal structure revealed that the tumor cells were derived from a single ancestral cell, but that subsequent evolution occurred, leading to two distinct tumor cell subpopulations. By analyzing recurrently mutant genes in an additional cohort of 99 TCC tumors, we identified genes that might play roles in the maintenance of the ancestral clone and in the muscle-invasive capability of subclones of this bladder cancer, respectively.This work provides a new approach of investigating the genetic details of bladder tumoral changes at the single-cell level and a new method for assessing bladder cancer evolution at a cell-population level.Bladder cancer (BC) is among the top ten most common cancers in the world; and transitional cell carcinoma (TCC) is the most common form, presenting in 90% of diagnosed BC [1]. Previous studies have indicated that the development of TCC involves multiple steps [2-4], but the key mutations and how this process occurs remain largely unknown. Clinical and genetic studies have classified TCC patients into two main categories: non-muscle-invasive TCCs (NMI-TCCs), which occur in approximately 70% of the patients and often carry mutations in the FGFR3 and RAS genes; and muscle-invasive TCCs (MI-TCCs), which occur in approximately 30% of the patients and often carry mutations in the TP53 and RB1 genes [5]. MI-TCC, however, is the form that is associated with a higher mortality rate [3], which makes this form of BC, though less common, of greater concern for developing the means to assess and ultimately devising viable treatments.Current information has indicated that there is a shared genetic pattern in TCCs among patient populations [6], but it has not yet been possible to apply this information to understand tumor formation within a patient. Moreove
%K Single-cell exome sequencing
%K Bladder cancer
%K Tumor evolution
%K Population genetics
%U http://www.gigasciencejournal.com/content/1/1/12